Cargando…
Truly continuous low pH viral inactivation for biopharmaceutical process integration
Continuous virus inactivation (VI) has received little attention in the efforts to realize fully continuous biomanufacturing in the future. Implementation of continuous VI must assure a specific minimum incubation time, typically 60 min. To guarantee the minimum incubation time, we implemented a pac...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187162/ https://www.ncbi.nlm.nih.gov/pubmed/32017010 http://dx.doi.org/10.1002/bit.27292 |
_version_ | 1783527115017158656 |
---|---|
author | Martins, Duarte L. Sencar, Jure Hammerschmidt, Nikolaus Flicker, Andreas Kindermann, Johanna Kreil, Thomas R. Jungbauer, Alois |
author_facet | Martins, Duarte L. Sencar, Jure Hammerschmidt, Nikolaus Flicker, Andreas Kindermann, Johanna Kreil, Thomas R. Jungbauer, Alois |
author_sort | Martins, Duarte L. |
collection | PubMed |
description | Continuous virus inactivation (VI) has received little attention in the efforts to realize fully continuous biomanufacturing in the future. Implementation of continuous VI must assure a specific minimum incubation time, typically 60 min. To guarantee the minimum incubation time, we implemented a packed bed continuous viral inactivation reactor (CVIR) with narrow residence time distribution (RTD) for low pH incubation. We show that the RTD does not broaden significantly over a wide range of linear flow velocities—which highlights the flexibility and robustness of the design. Prolonged exposure to acidic pH has no impact on bed stability, assuring constant RTD throughout long term operation. The suitability of the packed bed CVIR for low pH inactivation is shown with two industry‐standard model viruses, that is xenotropic murine leukemia virus and pseudorabies virus. Controls at neutral pH showed no system‐induced VI. At low pH, significant VI is observed, even after only 15 min. Based on the low pH inactivation kinetics, the continuous process is equivalent to traditional batch operation. This study establishes a concept for continuous low pH inactivation and, together with previous reports, highlights the versatility of the packed bed reactor for continuous VI, regardless of the inactivation method. |
format | Online Article Text |
id | pubmed-7187162 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71871622020-04-28 Truly continuous low pH viral inactivation for biopharmaceutical process integration Martins, Duarte L. Sencar, Jure Hammerschmidt, Nikolaus Flicker, Andreas Kindermann, Johanna Kreil, Thomas R. Jungbauer, Alois Biotechnol Bioeng ARTICLES Continuous virus inactivation (VI) has received little attention in the efforts to realize fully continuous biomanufacturing in the future. Implementation of continuous VI must assure a specific minimum incubation time, typically 60 min. To guarantee the minimum incubation time, we implemented a packed bed continuous viral inactivation reactor (CVIR) with narrow residence time distribution (RTD) for low pH incubation. We show that the RTD does not broaden significantly over a wide range of linear flow velocities—which highlights the flexibility and robustness of the design. Prolonged exposure to acidic pH has no impact on bed stability, assuring constant RTD throughout long term operation. The suitability of the packed bed CVIR for low pH inactivation is shown with two industry‐standard model viruses, that is xenotropic murine leukemia virus and pseudorabies virus. Controls at neutral pH showed no system‐induced VI. At low pH, significant VI is observed, even after only 15 min. Based on the low pH inactivation kinetics, the continuous process is equivalent to traditional batch operation. This study establishes a concept for continuous low pH inactivation and, together with previous reports, highlights the versatility of the packed bed reactor for continuous VI, regardless of the inactivation method. John Wiley and Sons Inc. 2020-02-24 2020-05 /pmc/articles/PMC7187162/ /pubmed/32017010 http://dx.doi.org/10.1002/bit.27292 Text en © 2020 The Authors. Biotechnology and Bioengineering Published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | ARTICLES Martins, Duarte L. Sencar, Jure Hammerschmidt, Nikolaus Flicker, Andreas Kindermann, Johanna Kreil, Thomas R. Jungbauer, Alois Truly continuous low pH viral inactivation for biopharmaceutical process integration |
title | Truly continuous low pH viral inactivation for biopharmaceutical process integration |
title_full | Truly continuous low pH viral inactivation for biopharmaceutical process integration |
title_fullStr | Truly continuous low pH viral inactivation for biopharmaceutical process integration |
title_full_unstemmed | Truly continuous low pH viral inactivation for biopharmaceutical process integration |
title_short | Truly continuous low pH viral inactivation for biopharmaceutical process integration |
title_sort | truly continuous low ph viral inactivation for biopharmaceutical process integration |
topic | ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187162/ https://www.ncbi.nlm.nih.gov/pubmed/32017010 http://dx.doi.org/10.1002/bit.27292 |
work_keys_str_mv | AT martinsduartel trulycontinuouslowphviralinactivationforbiopharmaceuticalprocessintegration AT sencarjure trulycontinuouslowphviralinactivationforbiopharmaceuticalprocessintegration AT hammerschmidtnikolaus trulycontinuouslowphviralinactivationforbiopharmaceuticalprocessintegration AT flickerandreas trulycontinuouslowphviralinactivationforbiopharmaceuticalprocessintegration AT kindermannjohanna trulycontinuouslowphviralinactivationforbiopharmaceuticalprocessintegration AT kreilthomasr trulycontinuouslowphviralinactivationforbiopharmaceuticalprocessintegration AT jungbaueralois trulycontinuouslowphviralinactivationforbiopharmaceuticalprocessintegration |